Chinagene Announces IND Acceptance of ZVS203e, China's First In Vivo AAV Gene-Editing Therapy for RHO-Associated Retinitis Pigmentosa

Recently,CHIGENOVO Co., Ltd.'s Gene-Editing Therapeutic Drug ZVS203e Injection IND Application Accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)ZVS203e Injection is a Class 1 innovative drug developed based on gene editing technology, intended for the treatment of retinitis pigmentosa caused by RHO gene mutations.It is the first in vivo AAV gene editing treatment product accepted in China.。

CHIGENOVO Co., Ltd. is a national high-tech enterprise specializing in genetic eye disease gene diagnosis and gene therapy drug development, committed to providing "one-stop" services of precise diagnosis and treatment for patients with hereditary eye diseases. CHIGENOVO has established a genetic eye disease database and large cohorts based on its diagnostic platform, summarizing the mutation spectrum of Chinese patients to provide therapeutic targets for drug development. On this basis, it develops drugs with independent intellectual property rights, including gene replacement therapy and gene editing therapy, striving to achieve a "from zero to one" breakthrough. The team currently has nearly 100 members and has established target screening, basic research, animal experiment validation, stem cell validation, and AAV.A complete drug development system, including virus research and production, clinical trial operations, and drug registration submissions.